Close Menu

Gates Foundation

The funding will help the company further develop its INSPECTR molecular diagnostic platform into a test that can be used in various settings.

The initiative will build up pathogen sequencing capacity through investment from the Gates Foundation, Microsoft, Illumina, and Oxford Nanopore.

Millions of Tests

The World Health Organization will be providing low-cost COVID-19 tests to low- and middle-income nations, according to Reuters.

Stopped It

The Food and Drug Administration's decision to halt a SARS-CoV-2 study has drawn criticism, according to Stat News.

At the Economist and his own site, Bill Gates discusses the scientific advances needed to address the pandemic and what comes next.

The method can be used with isothermal amplification and paper-based readouts to detect infectious disease drug resistance in low-resource areas.

For the Accelerator

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

And Then for All

NIH Director Francis Collins describes at Forbes how the agency is working with the Bill & Melinda Gates Foundation to develop gene-based treatments for sickle cell disease and HIV for sub-Saharan Africa.

According to the Seattle Times, the Bill & Melinda Gates Foundation is to enable home testing kits for SARS-CoV-2 to the Seattle area.

The funding comes from the Bill and Melinda Gates Foundation, which previously provided the company with $500,000 for the test's initial development.

Pages

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.